StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Carbutamide

HCID 178824797
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
1246820-50-7
Standard-SMILES
CCCCNC(=O)NS(=O)(=O)c1ccc(N)cc1
InChIKey
VDTNNGKXZGSZIP-UHFFFAOYSA-N
Summenformel
C11H17N3O3S
Durchschnittliche Molmasse
271,34 g/mol

Überblick

Carbutamide is a member of benzenes and a sulfonamide.

Namen und Bezeichner

Bevorzugter Name
Carbutamide
IUPAC
1-(4-aminophenyl)sulfonyl-3-butylurea
Englischer Name
Carbutamide-d9
Summenformel
C11H17N3O3S
Molmasse
271.33598

Namen und Synonyme

Carbutamide339-43-5GlybutamideEmedanInvenolButisulfinaGlucidoralGlucofrenDiaboralOrasulinBurcolNadisan
Weitere Namen anzeigen
CarbutaBZ 55-d9Burcol-d9Bucrol-d9Alentin-d9Bucarban-d9Bukarban-d9Butisulfina-d9Carbutamide-d9[2H9]-Carbutamide
AminophenurobutaneBukarbanNorboralAlentinBucrolInbutonNadizanOranyl

Datenbank-Bezeichner

CAS
1246820-50-7
ChEMBL
CHEMBL448570
ChEBI
CHEBI:135118
UNII
E3K8P4869P
EC Number
206-424-4
Nikkaji
J5.684G

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

XLogP
1
Polarare Oberfläche (TPSA)
110 Ų
H-Brücken-Donoren
3
H-Brücken-Akzeptoren
4
Frei drehbare Bindungen
5
Schwere Atome
18
Formalladung
0
Komplexität
356

Experimentelle und physikochemische Eigenschaften

SpringerMaterials PropertiesCrystal structure
LogP · 2 Einträge

log Kow= 1.01

1.18

Color/FormCrystals
Solubility · 2 Einträge

Sol in water at pH 5 to 8.

In water, 535 mg/l @ 37 °C

Melting Point144-145 °C
Collision Cross Section165.0 Ų [M-H]- [CCS Type: DT; Buffer gas: N2; Ionization: ESI-; Dataset: TOXCAST; Source Identifier: DTXSID8022741]

Physikochemische Eigenschaften

Schmelzpunkt
137 · 137-140°C
storage temp.
Refrigerator
Löslichkeit
DMSO (Slightly), Methanol (Slightly)
Aggregatzustand
Solid

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Warning

H315 (97.5%): Causes skin irritation [Warning Skin corrosion/irritation]

P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 40 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Other Safety InformationIMAP assessments - Benzenesulfonamide, 4-amino-N-[(butylamino)carbonyl]-: Human health tier I assessment
FDA Requirements · 1 Eintrag

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

Hazard Classes and CategoriesSkin Irrit. 2 (97.5%)

Sicherheit und Schutzausrüstung

Disposal Methods · 1 Eintrag

SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.

Toxikologische Informationen

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 2 Einträge

A - Alimentary tract and metabolism

QA - Alimentary tract and metabolism

Mechanism of Action · 1 Eintrag

SULFONYLUREAS STIMULATE ISLET TISSUE TO SECRETE INSULIN. ... SULFONYLUREAS CAUSE DEGRANULATION OF THE BETA CELLS, A PHENOMENON ASSOCIATED WITH INCR RATE OF SECRETION OF INSULIN. ...THEY ARE EFFECTIVE IN INSULIN-INDEPENDENT DIABETIC PATIENTS IN WHOM THE PANCREAS RETAINS THE CAPACITY TO SECRETE INSULIN. /SULFONYLUREAS/

Metabolism/Metabolites · 2 Einträge

...IN MAN APPROX ONE-THIRD OF THE EXCRETED DOSE IS REPRESENTED BY THE N-ACETYLATED METABOLITE. LARGE SPECIES VARIATIONS HAVE BEEN DETECTED; THE RABBIT PRODUCES SIGNIFICANT AMT...WHILE MONKEY & DOGS ARE LOW OR VERY LOW ACETYLATORS & MAN OCCUPIES AN INTERMEDIATE POSITION.

THEY ARE HYDROXYLATED IN THE LIVER TO ACTIVE & INACTIVE PRODUCTS WHICH ARE ALMOST TOTALLY EXCRETED IN THE URINE. /SULFONYLUREAS/

MeSH Pharmacological ClassificationSubstances which lower blood glucose levels.
Absorption, Distribution and Excretion · 2 Einträge

THE SULFONYLUREAS ARE READILY ABSORBED FROM THE GI TRACT. THE MOST IMPORTANT DIFFERENCE AMONG THE SULFONYLUREAS, FOR CLINICAL PURPOSE, IS IN THEIR DURATION OF ACTION... /SULFONYLUREAS/_

SULFONYLUREAS ARE LARGELY BOUND TO PLASMA PROTEINS & ARE DISTRIBUTED IN THE EXTRACELLULAR SPACE. /SULFONYLUREAS/

Verwendung und Herstellung

Uses · 2 Einträge

Therap cat: Antidiabetic

MEDICATION (VET)

U.S. Production · 2 Einträge

(1979) NOT PRODUCED COMMERCIALLY IN U.S.

(1981) NOT PRODUCED COMMERCIALLY IN U.S.

Zugehörige Reaktionen

0
Reaktionsaufzeichnung erstellen
Noch keine zugehörigen Reaktionen

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
Farbe
White to Off-White
Interactions · 5 Einträge

...SODIUM CARBONATE REDUCED...DRUG'S TERATOGENIC & LETHAL ACTION IN RAT.

DRUGS THAT MAY INCR RISK OF HYPOGLYCEMIA FROM SULFONYLUREAS INCL OTHER HYPOGLYCEMIC AGENTS, SULFONAMIDES, PROPRANOLOL, SALICYLATES, CLOFIBRATE, PHENYLBUTAZONE, PROBENECID, DICUMAROL, CHLORAMPHENICOL, MONOAMINE OXIDASE INHIBITORS, & ALCOHOL. /SULFONYLUREAS/

ALCOHOL & SALICYLATES BECAUSE OF THEIR DIRECT HYPOGLYCEMIC ACTION, MAY PRECIPITATE HYPOGLYCEMIC COMA IN PT RECEIVING SULFONYLUREAS. ... PROPRANOLOL, BY INTERFERING WITH GLYCOGENOLYSIS & GLUCAGON RELEASE, ENHANCES THE HYPOGLYCEMIC ACTION OF SULFONYLUREAS. /SULFONYLUREAS/

THE SULFONYLUREA-MEDIATED SECRETION OF INSULIN CAN BE MODIFIED BY CONCOMITANT PERFUSION OF SECOND DRUG THAT DISPLACES SULFONYLUREA IN PANCREAS. THUS, THE DRUG INTERACTION AT THE TARGET ORGAN OR RECEPTOR SITE SHOULD BE UNDERSTOOD TO PROVIDE ADEQUATE DRUG THERAPY.

For more Interactions (Complete) data for 1-BUTYL-3-SULFANILYLUREA (8 total), please visit the HSDB record page.

Human Toxicity ExcerptsFOURTEEN PT TREATED WITH CARBUTAMIDE HAD TRANSIENT HEMIPARESIS. 4 HAD IRREVERSIBLE NEUROLOGIC DEFECTS, & 5 EXPIRED AFTER HYPOGLYCEMIC COMA. NEARLY 70 OF THE EPISODES OCCURRED WITHIN THE FIRST 15 DAYS OF THE SULFONYLUREA TREATMENT.
Non-Human Toxicity Excerpts · 5 Einträge

CARBUTAMIDE...HAS BEEN SHOWN TO BE TOXIC TO THE EYES OF RATS WHEN CHRONICALLY ADMIN AT DOSAGES 5 TO 40 TIMES THOSE EMPLOYED IN TREATMENT OF HUMAN BEINGS. IT HAS CAUSED OPACIFICATION OF LENS & CORNEA, VASCULARIZATION OF CORNEA, & POSTERIOR SYNECHIAS, USUALLY IN 8-24 MO. ... IN DOGS SIMILAR TREATMENT HAS NOT AFFECTED EYES.

...CLEFT PALATE, EYE DEFECTS & GENERALIZED EDEMA /WAS FOUND/ IN RAT FETUSES WHOSE MOTHERS RECEIVED 500 MG/DAY FOR 1, 2 OR 3 DAYS DURING THE EMBRYONIC PERIOD.

...800 MG/KG FROM 1ST THROUGH 12TH DAY /OF GESTATION/ IN RATS PRODUCED 10-33% MALFORMED FETUSES. MAJORITY OF DEFECTS INVOLVED EYE & INCL ABSENCE OF OPTIC NERVE. SOME NERVOUS SYSTEM DEFECTS...REPORTED. ... /ANOTHER INVESTIGATOR/...CAUSED CLEFT PALATES & HYDROCEPHALUS WITH THIS SUBSTANCE IN RATS.

CARBUTAMIDE WAS ADMIN PARENTERALLY IN DOSES OF 100 MG/KG BODY WT & WAS WELL TOLERATED. FOLLOWING TREATMENT ON DAYS 4, 5, & 6 NO ABNORMALITIES WERE SEEN IN 6 1/2 DAY BLASTOCYSTS. NO EFFECT ON FETAL DEVELOPMENT.

For more Non-Human Toxicity Excerpts (Complete) data for 1-BUTYL-3-SULFANILYLUREA (13 total), please visit the HSDB record page.

Regulatorische Informationen

FDA Requirements · 1 Eintrag

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

Methods of Manufacturing · 2 Einträge

...from butylurea and sulfanilamide: Samaniego, Spanish patent 229,696 (1956), CA 51, 7413 (1957); Haack, Hagedorn, US patent 2,907,692 (1959 to Boehringer, Mann). Alternate route: Haack, Hagedorn, US patent 2,997,375 (1961 to Boehringer, Mann).

REACTION OF BUTYLUREA WITH SULFANILAMIDE

General Manufacturing InformationBenzenesulfonamide, 4-amino-N-[(butylamino)carbonyl]-: INACTIVE

Anwendungen

VerwendenLabelled Carbutamide (C183300). Antidiabetic.